Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

China

- PMLiVE

AZ gets rapid approval in China for Tagrisso

Lung cancer treatment becomes first medicine to pass through the country's Priority Review pathway

Pharma China Annual Forum 2017

We are delighted to be presenting a paper at the Pharma China Annual Forum on 14th April 2017 in Shanghai, China.

Research Partnership

National Institute for Health and Care Excellence NICE logo

Amicus gets NICE green light for Fabry drug

Oral therapy alternative Galafold approved for routine NHS use

AstraZeneca AZ

Generic version of AZ’s Iressa launched in China

Qilu Pharma’s Yiruike licensed as first-line NSCLC treatment

- PMLiVE

NICE blocks second Alexion rare disease drug in a week

Says high cost and “considerable uncertainties” over long-term benefits prohibit routine NHS use

ABPI London offices

UK pharma slams new drug evaluation plans

ABPI and BIA oppose "arbitrary" proposal to impose £100,000 QALY limit on rare disease therapies

ABPI London offices

UK pharma slams new drug evaluation plans

ABPI and BIA oppose "arbitrary" proposal to impose £100,000 QALY limit on rare disease therapies

- PMLiVE

A rare talent

Shire’s Sebastian Stachowiak on dealing with change and working for a fit-for-purpose orphan drug environment

- PMLiVE

Kite bags $90m upfront in two Asian deals for lead CAR-T drug

Partners with Daiichi Sankyo and Fosun Pharma to focus in on non-Hodgkin lymphoma

Eli Lilly HQ

Lilly streamlines and culls leadership roles

Merges Europe and emerging markets interests and expands diabetes and oncology

J&J collaborates on consumer health device accelerator

Partners with Shenzhen-based investor firm HAX

Biogen Idec building

FDA approves Biogen’s Spinraza for spinal muscular atrophy

Analysts predict blockbuster sales as drug is priced at $750,000 for first year of treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links